Skip to content

Biohaven BHVN Cash ratio

Cash ratio at other companies

Eli Lilly logo
Eli LillyLLY
0.1×0.0×
Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
13.7×+10.1×
Rapport Therapeutics, Inc. logo
Rapport Therapeutics, Inc.RAPP
4.4×-1.8×
Vir Biotechnology, Inc. logo
Vir Biotechnology, Inc.VIR
3.8×+1.2×
uniQure logo
uniQureQURE
2.4×-3.6×
Roivant Sciences logo
Roivant SciencesROIV
+4.4×

Other financials

Income statement

See full
Operating income-$130.4M+41.1%
Net income-$130.5M+41.1%
EPS (diluted)-$0.88+59.4%

Balance sheet

See full
Cash & equivalents$277.1M+170%
Total debt$286.2M+706%
Total equity$129.5M-50.1%
Total assets$466.4M+1.6%

Cash flow

See full
Operating cash flow-$149.9M+9.2%
CapEx--100%
Free cash flow-$149.9M+9.5%

Valuation

See full
Market cap$2.25B-48.1%

Returns & leverage

See full
Return on equity-333%+17.9pp
Debt / equity2.2×+2.1×
Current ratio7.4×+5.1×

Where this comes from

Calculated from Biohaven’s reported figures.

Based on the most recent quarter.

The official record: Biohaven’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Biohaven's cash ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Biohaven's cash ratio?
Biohaven (BHVN) reported cash ratio of 5.3× in Q1 2026.
How has Biohaven's cash ratio changed year-over-year?
Biohaven's cash ratio increased by 750.0% year-over-year, from 0.6× to 5.3×.
What is the long-term trend for Biohaven's cash ratio?
Over 4 years (2021 to 2025), Biohaven's cash ratio has grown at a 2.2% compound annual growth rate (CAGR), from 1.8× to 2×.
What does cash ratio mean?
Cash and equivalents divided by current liabilities at the quarter end. The most conservative liquidity measure — what the company could pay immediately with cash on hand.